- India
- /
- Life Sciences
- /
- NSEI:INNOVACAP
Innova Captab Limited's (NSE:INNOVACAP) 25% Share Price Plunge Could Signal Some Risk
Innova Captab Limited (NSE:INNOVACAP) shareholders won't be pleased to see that the share price has had a very rough month, dropping 25% and undoing the prior period's positive performance. Looking at the bigger picture, even after this poor month the stock is up 47% in the last year.
In spite of the heavy fall in price, given around half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may still consider Innova Captab as a stock to potentially avoid with its 34.7x P/E ratio. However, the P/E might be high for a reason and it requires further investigation to determine if it's justified.
Recent times have been advantageous for Innova Captab as its earnings have been rising faster than most other companies. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. If not, then existing shareholders might be a little nervous about the viability of the share price.
Check out our latest analysis for Innova Captab
Is There Enough Growth For Innova Captab?
In order to justify its P/E ratio, Innova Captab would need to produce impressive growth in excess of the market.
If we review the last year of earnings growth, the company posted a terrific increase of 67%. The latest three year period has also seen an excellent 67% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.
Looking ahead now, EPS is anticipated to climb by 19% during the coming year according to the two analysts following the company. That's shaping up to be materially lower than the 26% growth forecast for the broader market.
In light of this, it's alarming that Innova Captab's P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than analysts indicate and aren't willing to let go of their stock at any price. There's a good chance these shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.
The Final Word
Innova Captab's P/E hasn't come down all the way after its stock plunged. Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
We've established that Innova Captab currently trades on a much higher than expected P/E since its forecast growth is lower than the wider market. Right now we are increasingly uncomfortable with the high P/E as the predicted future earnings aren't likely to support such positive sentiment for long. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable.
Before you settle on your opinion, we've discovered 1 warning sign for Innova Captab that you should be aware of.
Of course, you might also be able to find a better stock than Innova Captab. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:INNOVACAP
Innova Captab
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally.
Flawless balance sheet with high growth potential.
Market Insights
Community Narratives


